Your browser doesn't support javascript.
loading
Chemical Exploration of a Highly Selective Scaffold with Activity against Intracellular Mycobacterium tuberculosis.
Njikan, Samuel; Ahmed, Sara; Manning, Alyssa; Awasthi, Divya; Ovechkina, Yulia; Chowdhury, Sultan; Butts, Arielle; Parish, Tanya.
Afiliação
  • Njikan S; Infectious Disease Research Institute, Seattle, Washington, USA.
  • Ahmed S; Center for Global Infectious Disease Research Seattle, Seattle Children's Research Institute, Seattle, Washington, USA.
  • Manning A; Infectious Disease Research Institute, Seattle, Washington, USA.
  • Awasthi D; Center for Global Infectious Disease Research Seattle, Seattle Children's Research Institute, Seattle, Washington, USA.
  • Ovechkina Y; Infectious Disease Research Institute, Seattle, Washington, USA.
  • Chowdhury S; Infectious Disease Research Institute, Seattle, Washington, USA.
  • Butts A; Infectious Disease Research Institute, Seattle, Washington, USA.
  • Parish T; Center for Global Infectious Disease Research Seattle, Seattle Children's Research Institute, Seattle, Washington, USA.
Microbiol Spectr ; 10(3): e0116122, 2022 06 29.
Article em En | MEDLINE | ID: mdl-35612308
ABSTRACT
We previously identified a phenylthiourea series with activity against intracellular Mycobacterium tuberculosis using a high-throughput, high-content assay. We conducted a catalog structure-activity relationship study with a collection of 35 analogs. We identified several thiourea derivatives with excellent potency against intracellular bacteria and good selectivity over eukaryotic cells. Compounds had much lower activity against extracellular bacteria, which was not increased by using cholesterol as the sole carbon source. Compounds were equally active against strains with mutations in QcrB or MmpL3, thereby excluding common, promiscuous targets as the mode of action. The phenylthiourea series represents a good starting point for further exploration to develop novel antitubercular agents. IMPORTANCE Mycobacterium tuberculosis is responsible for the highest number of deaths from a bacterial pathogen, with >1.5 million in 2020. M. tuberculosis is a sophisticated pathogen that can replicate inside immune cells. There is an urgent need for new drugs to combat M. tuberculosis and to shorten therapy from 6 to 24 months. We have identified a series of molecules that inhibit the growth of M. tuberculosis inside macrophages; we tested a number of derivatives to link structural features to biological activity. The compounds are likely to have novel mechanism of action and so could be developed as new agents for drug-resistant tuberculosis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose dos Linfonodos / Tuberculose Resistente a Múltiplos Medicamentos / Mycobacterium tuberculosis Limite: Humans Idioma: En Revista: Microbiol Spectr Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose dos Linfonodos / Tuberculose Resistente a Múltiplos Medicamentos / Mycobacterium tuberculosis Limite: Humans Idioma: En Revista: Microbiol Spectr Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos